Home > Riviste > Minerva Cardioangiologica > Fascicoli precedenti > Minerva Cardioangiologica 2018 August;66(4) > Minerva Cardioangiologica 2018 August;66(4):386-90

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

ORIGINAL ARTICLE   

Minerva Cardioangiologica 2018 August;66(4):386-90

DOI: 10.23736/S0026-4725.18.04637-6

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Behçet syndrome: effects of Pycnogenol® supplementation during regression phases

Shu HU 1, 2, Gianni BELCARO 1, 2 , Andrea LEDDA 1, 2, Marcello CORSI 1, 2, Roberto COTELLESE 1, 2, Beatrice FERAGALLI 1, 2, Morio HOSOI 1, 2, Mark DUGALL 1, 2, Patrizia TORINO-RODRIGUEZ 1, 2, Maria R. CESARONE 1, 2

1 IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy; 2 International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy


PDF


BACKGROUND: The aim of this comparative registry study was to evaluate the supplementation with Pycnogenol® in subjects with Behçet syndrome (BS) with symptoms impairing their quality of life despite being in a remitting phase of the disease.
METHODS: Thirty-four patients with a confirmed diagnosis of BS were divided into the control group (without supplement) or the active group, in this specific case using Pycnogenol® (Horphag Research LTD) supplement at the daily dose of 150 mg (50 mg tid) for 4 weeks.
RESULTS: All subjects receiving Pycnogenol® reported a significant decrease in symptoms, such as burning/pain due to dryness and ulcerations (P<0.05). In addition, Pycnogenol® showed important anti-inflammatory activity by decreasing ESR, leucocytosis and Pathergy Test response.
CONCLUSIONS: Pycnogenol® may be a useful supplementation for the management of BS.


KEY WORDS: Behçet syndrome - Pycnogenol® - Dietary supplements, inflammation

inizio pagina